| Thomas Jay Failinger, MD | |
|
300 E Boyd Ave Ste 201, Greenfield, IN 46140-2818 | |
| (317) 462-5112 | |
| Not Available |
| Full Name | Thomas Jay Failinger |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 39 Years |
| Location | 300 E Boyd Ave Ste 201, Greenfield, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164496501 | NPI | - | NPPES |
| 200016610 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 01037800A (Indiana) | Primary |
| 207R00000X | Internal Medicine | 01037800A (Indiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hancock Regional Hospital | Greenfield, IN | Hospital |
| Ascension St Vincent Hospital | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Vincent Medical Group Inc | 7012047640 | 625 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
All babies should be put to their mother's breast within an hour of their birth for breast feeding recommends the World Health Organization and UNICEF. The first milk or the colostrum is known to have several health and nutritional benefits for the baby. A new report has found that nearly 60 percent of the babies are not breast fed within the first hour after their birth. This raises their risk of later illness and even death.
An open label Phase 3 study conducted at Ann & Robert H. Lurie Children's Hospital of Chicago and other centers established that a combination of cystic fibrosis drugs lumacaftor and ivacaftor is safe and effective in children aged 2-5 years, whose disease is caused by two copies of F508del-CFTR gene mutation - the most common and severe form of cystic fibrosis.
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded 2010 Toshiba America Medical Systems/RSNA grants to Kenneth S. Lee, M.D., Nitin Ohri, M.D., and Ben Paxton, M.D. The grants are made possible by Toshiba's support of the RSNA R&E Foundation.
› Verified 8 days ago
| Entity Name | St Vincent Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144513375 PECOS PAC ID: 7012047640 Enrollment ID: O20100609000045 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
All babies should be put to their mother's breast within an hour of their birth for breast feeding recommends the World Health Organization and UNICEF. The first milk or the colostrum is known to have several health and nutritional benefits for the baby. A new report has found that nearly 60 percent of the babies are not breast fed within the first hour after their birth. This raises their risk of later illness and even death.
An open label Phase 3 study conducted at Ann & Robert H. Lurie Children's Hospital of Chicago and other centers established that a combination of cystic fibrosis drugs lumacaftor and ivacaftor is safe and effective in children aged 2-5 years, whose disease is caused by two copies of F508del-CFTR gene mutation - the most common and severe form of cystic fibrosis.
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded 2010 Toshiba America Medical Systems/RSNA grants to Kenneth S. Lee, M.D., Nitin Ohri, M.D., and Ben Paxton, M.D. The grants are made possible by Toshiba's support of the RSNA R&E Foundation.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Jay Failinger, MD 300 E Boyd Ave Ste 201, Greenfield, IN 46140-2818 Ph: () - | Thomas Jay Failinger, MD 300 E Boyd Ave Ste 201, Greenfield, IN 46140-2818 Ph: (317) 462-5112 |
News Archive
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.
All babies should be put to their mother's breast within an hour of their birth for breast feeding recommends the World Health Organization and UNICEF. The first milk or the colostrum is known to have several health and nutritional benefits for the baby. A new report has found that nearly 60 percent of the babies are not breast fed within the first hour after their birth. This raises their risk of later illness and even death.
An open label Phase 3 study conducted at Ann & Robert H. Lurie Children's Hospital of Chicago and other centers established that a combination of cystic fibrosis drugs lumacaftor and ivacaftor is safe and effective in children aged 2-5 years, whose disease is caused by two copies of F508del-CFTR gene mutation - the most common and severe form of cystic fibrosis.
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation awarded 2010 Toshiba America Medical Systems/RSNA grants to Kenneth S. Lee, M.D., Nitin Ohri, M.D., and Ben Paxton, M.D. The grants are made possible by Toshiba's support of the RSNA R&E Foundation.
› Verified 8 days ago
Kerri A. Kissell, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Sq Ste 2200, Greenfield, IN 46140 Phone: 317-462-6662 Fax: 317-468-6275 | |
Thomas L Whittaker, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: One Memorial Sq, Ste 50, Greenfield, IN 46140 Phone: 317-467-7100 Fax: 317-467-0209 | |
Charles R Taylor, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave Ste 201, Greenfield, IN 46140 Phone: 317-462-5112 Fax: 317-462-5122 | |
Dr. Stephen J. Flink, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 300 E Boyd Ave Ste 120, Greenfield, IN 46140 Phone: 317-462-3441 Fax: 317-477-6316 | |
Bryce S Lynn, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 300 E Boyd Ave Ste 201, Greenfield, IN 46140 Phone: 317-462-5112 | |
Drew Dust, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Memorial Sq Ste 2200, Greenfield, IN 46140 Phone: 317-462-6662 Fax: 317-468-6275 |